Amyloid PET in Patients With Mild Cognitive Impairment and Early Dementia
This study is testing if a special brain scan can help doctors understand the causes of memory problems in people with mild cognitive impairment and early dementia.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Ghent Academic / other |
| Drugs / interventions | aducanumab, donanemab |
| Locations | 1 site (Ghent) |
| Trial ID | NCT06402370 on ClinicalTrials.gov |
What this trial studies
Processing failed - manual review needed
Who should consider this trial
Good fit: Unknown
Not a fit: Unknown
Why it matters
Potential benefit: Unknown
How similar studies have performed: Unknown
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with mild cognitive impairment or early stage dementia who have a MRI and \[18F\]FDG PET/CT scan as part of routine clinical work-up Exclusion Criteria: * Patient is not able to understand the study Patient is not able to lie still in the scanner for at least 30 minutes Pregnancy or breastfeeding
Where this trial is running
Ghent
- Van Weehaeghe D — Ghent, Belgium (Recruiting)
Study contacts
- Principal investigator: Donatienne Van Weehaeghe, MD PhD — UZ Gent
- Study coordinator: Van Weehaeghe Donatienne
- Email: donatienne.vanweehaeghe@uzgent.be
- Phone: +32 9 332 30 27
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions
MCI
Last reviewed 2026-06-13 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.